|
|
|
|
| LEADER |
03248nma a2200421 u 4500 |
| 001 |
EB001980596 |
| 003 |
EBX01000000000000001143498 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9782889454617
|
| 020 |
|
|
|a 978-2-88945-461-7
|
| 100 |
1 |
|
|a Francesca Chiodi
|
| 245 |
0 |
0 |
|a HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies
|h Elektronische Ressource
|
| 260 |
|
|
|b Frontiers Media SA
|c 2018
|
| 300 |
|
|
|a 1 electronic resource (171 p.)
|
| 653 |
|
|
|a Gene Expression
|
| 653 |
|
|
|a BAFF
|
| 653 |
|
|
|a clinical potential of HIV-1 antibodies
|
| 653 |
|
|
|a auto-antibodies to CCR5
|
| 653 |
|
|
|a mucosal IgA responses
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a B cells
|
| 653 |
|
|
|a HIV-1 vaccine targets
|
| 653 |
|
|
|a neutralizing and non neutralizing HIV-1 antibodies
|
| 653 |
|
|
|a maternal HIV antibodies
|
| 653 |
|
|
|a CXCL13
|
| 653 |
|
|
|a FcRL4
|
| 700 |
1 |
|
|a Gabriella Scarlatti
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 490 |
0 |
|
|a Frontiers Research Topics
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3389/978-2-88945-461-7
|
| 856 |
4 |
0 |
|u https://www.frontiersin.org/research-topics/5357/hiv-induced-damage-of-b-cells-and-production-of-hiv-neutralizing-antibodies
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/49485
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Multiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarged during HIV-1 infection. Antibodies with the capacity to neutralize a broad range of HIV-1 isolates can be detected only in a minority of infected patients, after a year or more from acute infection. An open question is whether the inability of producing neutralizing HIV-1 antibodies is somehow linked to the B cell immunopathology observed in patients. In this research topic we invited scientists to summarize the current state of knowledge on regulation and development of B cells and antibody responses during HIV-1 infection; fifteen contributions were received comprising both reviews and original articles. The articles are related to B cell dysfunctions identified in HIV-1 infected individuals, production of different types of antibodies (neutralizing versus non neutralizing, and of different isotypes) in vivo during HIV-1 infection and the biological factors which may impact on this process, clinical potential and applications of anti-HIV antibodies and how to achieve neutralizing antibody responses to HIV-1 epitopes upon vaccination. The topic has gathered articles on front-line research undertaken in the field of B cells and antibodies in HIV-1 infection. It is our hope that the collection of articles presented in this book may be useful for new and experienced scholars in the field and add a piece to the complex puzzle of knowledge needed for the development of an HIV-1 vaccine.
|